MIAMI--(BUSINESS WIRE)--OrganaBio, LLC, announces initiation of GMP manufacturing operations at its new cell therapy manufacturing facility, launching a new paradigm in contract and development ...

The main market opportunities include expanding pharmaceutical manufacturing that adheres to dynamic global GMP standards, conducting comprehensive training programs to ensure compliance, and ...

WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) ...

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with ...

In this webinar, Gonçalo Regalo discusses how raw materials, media composition, and process design influence scalable cell ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian ...

Manufacturers are usually subjected to a diverse variety of regulations typically established by international and regional bodies. Failure to comply can result in the loss of authorization and ...

FDA recently published a Federal Register notice announcing a public listening session on good manufacturing practices (GMPs) for cosmetic products under the Modernization of Cosmetics Regulation Act ...